Gianni Carraro
Overview
Explore the profile of Gianni Carraro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
2415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reynolds S, Hill C, Alsudayri A, Stack J, Shontz K, Carraro G, et al.
Stem Cells Transl Med
. 2024 Nov;
14(1).
PMID: 39485996
Cystic fibrosis transmembrane conductance regulator (CFTR) gene editing and transplantation of CFTR-gene corrected airway basal cells has the potential to cure CF lung disease. Although mouse studies established that cell...
2.
Pintus G, Vitturi N, Carraro G, Lenzini L, Gugelmo G, Fasan I, et al.
J Clin Med
. 2024 Aug;
13(15).
PMID: 39124570
Background: Methylmalonic Aciduria (MA) without homocystinuria (or isolated MA) is a group of rare inherited metabolic disorders which leads to the accumulation of methylmalonic acid (MMA), a toxic molecule that...
3.
Baciga F, Marchi G, Caccia F, Momente C, Esposito P, Aucella F, et al.
Kidney Blood Press Res
. 2024 Jul;
49(1):699-717.
PMID: 39068916
Background: Fabry disease (FD) is a multisystem, monogenic, X-linked storage disorder caused by mutations in the GLA gene, resulting in reduced alfa-galactosidase A enzyme activity. This effect leads to the...
4.
Cacciapuoti M, Bertoldi G, Caputo I, Driussi G, Carraro G, Calo L
J Nephrol
. 2024 Jun;
37(5):1201-1207.
PMID: 38878155
Fabry disease is a rare X-linked disease characterized by deficient expression and activity of alpha-galactosidase A with consequent lysosomal accumulation of glycosphingolipids, particularly globotriaosylceramide in various organs. Currently, enzyme replacement...
5.
Carraro G, di Vico V, Martinetti L, Bettin E, Cacciapuoti M, Stefanelli L, et al.
Clin Drug Investig
. 2024 Mar;
44(4):289-291.
PMID: 38430434
No abstract available.
6.
Lenzini L, Iori E, Vettore M, Gugelmo G, Radu C, Padoan A, et al.
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202225
Fabry disease (FD) is an X-linked lysosome storage disease that results in the accumulation of globotriaosylceramide (Gb3) throughout the body leading to irreversible target organ damage. As the role of...
7.
Beppu A, Zhao J, Yao C, Carraro G, Israely E, Coelho A, et al.
Nat Commun
. 2023 Sep;
14(1):5814.
PMID: 37726288
Epithelial plasticity has been suggested in lungs of mice following genetic depletion of stem cells but is of unknown physiological relevance. Viral infection and chronic lung disease share similar pathological...
8.
Martino F, Pini S, Scaparrotta G, Schirinzi M, Gnappi M, Fragasso A, et al.
J Nephrol
. 2023 Jul;
36(7):2155-2158.
PMID: 37392330
No abstract available.
9.
Battaglia Y, Bulighin F, Zerbinati L, Vitturi N, Marchi G, Carraro G
J Clin Med
. 2023 Jun;
12(11).
PMID: 37297884
Fabry disease (FD) is a rare genetic disorder caused by a deficiency in the α-galactosidase A enzyme, which results in the globotriaosylceramide accumulation in many organs, including the kidneys. Nephropathy...
10.
Caputo I, Bertoldi G, Driussi G, Sgarabotto L, Carraro G, Stefanelli L, et al.
J Intern Med
. 2023 May;
294(2):238-240.
PMID: 37227252
No abstract available.